ArticleEuropean journal of nuclear medicine and molecular imaging2021
Grey zone amyloid burden affects memory function: the SCIENCe project.
Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Associations of plasma biomarkers of Alzheimer's disease pathology with modifiable risk factors and cognitive and functional outcomes: evidence from cross-sectional prediction and latent path analyses in the Bio-Hermes-001 cohort.Alzheimer's research & therapy · 2026Article
- Beyond binary classification: Comparing three region-based multi-phase Aβ staging systems.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Performance of a [Neurology · 2023Article
- Longitudinal change in ATN biomarkers in cognitively normal individuals.Alzheimer's research & therapy · 2022Article
- Subjective cognitive decline-related worries modulate the relationship between global amyloid load and gray matter volume in preclinical Alzheimer's disease.Brain imaging and behavior · 2022Article
- A three-range approach enhances the prognostic utility of CSF biomarkers in Alzheimer's disease.Alzheimer's & dementia (New York, N. Y.) · 2022Article
- Cognitive Decline Assessment: A Review From Medical Imaging Perspective.Frontiers in aging neuroscience · 2021Review
- Amyloid-related changes in fluency in patients with subjective cognitive decline.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine thresholds for amyloid beta pathology and evaluate associations with longitudinal memory performance with the aim to identify a grey zone of early amyloid beta accumulation and investigate its clinical relevance.
methodsWe included 162 cognitively normal participants with subjective cognitive decline from the SCIENCe cohort (64 ± 8 years, 38% F, MMSE 29 ± 1). Each underwent a dynamic [
resultsAs determined by visual assessment, 24% of 162 individuals were amyloid positive. Concordance with visual assessment was comparable but slightly higher for BP
conclusionWe provide evidence that not only high but also grey zone amyloid burden subtly impacts memory function. Therefore, in case a binary classification is required, we suggest using a relatively low threshold which includes grey zone amyloid pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.